Home Contact Sitemap

eRAM

encyclopedia of Rare Disease Annotation for Precision Medicine



   maple syrup urine disease
  

Disease ID 27
Disease maple syrup urine disease
Definition
An autosomal recessive inherited disorder with multiple forms of phenotypic expression, caused by a defect in the oxidative decarboxylation of branched-chain amino acids (AMINO ACIDS, BRANCHED-CHAIN). These metabolites accumulate in body fluids and render a "maple syrup" odor. The disease is divided into classic, intermediate, intermittent, and thiamine responsive subtypes. The classic form presents in the first week of life with ketoacidosis, hypoglycemia, emesis, neonatal seizures, and hypertonia. The intermediate and intermittent forms present in childhood or later with acute episodes of ataxia and vomiting. (From Adams et al., Principles of Neurology, 6th ed, p936)
Synonym
bckd - branched chain alpha-ketoacid dehydrogenase deficiency
bckd deficiency
branched chain alpha keto acid dehydrogenase deficiency
branched chain ketoacid dehydrogenase deficiency
branched chain ketoaciduria
branched-chain alpha-keto acid dehydrogenase deficiency
branched-chain ketoaciduria
branched-chain ketoacidurias
branched-chain ketonuria
disease maple syrup urine
keto acid decarboxylase deficiency
ketoacid decarboxylase deficiency
ketoacidaemia
ketoacidemia
ketoaciduria, branched-chain
ketoacidurias, branched-chain
maple syrup disease
maple syrup urine dis
maple syrup urine disease (disorder)
maple syrup urine disease [disease/finding]
maple syrup urine disease, nos
msu
msud
msud (maple syrup urine disease)
msud - maple syrup urine disease
msud maple syrup urine dis
oxo-acid decarboxylase deficiency
Orphanet
OMIM
DOID
UMLS
C0024776
MeSH
SNOMED-CT
Comorbidity
UMLS | Disease | Sentences' Count(Total Sentences:3)
C0679466  |  cognitive deficits  |  1
C0027765  |  neurological disorder  |  1
C0030305  |  pancreatitis  |  1
Curated Gene
Entrez_id | Symbol | Resource(Total Genes:5)
1738  |  DLD  |  CTD_human;GHR
594  |  BCKDHB  |  CLINVAR;GHR;ORPHANET;UniProtKB-KW;UNIPROT;CTD_human
1629  |  DBT  |  CLINVAR;GHR;ORPHANET;UniProtKB-KW;UNIPROT;CTD_human
593  |  BCKDHA  |  CLINVAR;GHR;ORPHANET;UniProtKB-KW;UNIPROT;CTD_human
587  |  BCAT2  |  CTD_human
Inferring Gene
Entrez_id | Symbol | Resource(Total Genes:5)
593  |  BCKDHA  |  CIPHER;CTD_human
594  |  BCKDHB  |  CIPHER;CTD_human
1629  |  DBT  |  CIPHER;CTD_human
1738  |  DLD  |  CTD_human
587  |  BCAT2  |  CTD_human
Text Mined Gene
Entrez_id | Symbol | Score | Resource(Total Genes:41)
31  |  ACACA  |  1.459  |  DISEASES
32  |  ACACB  |  2.052  |  DISEASES
36  |  ACADSB  |  3.112  |  DISEASES
586  |  BCAT1  |  3.29  |  DISEASES
587  |  BCAT2  |  4.751  |  DISEASES
53335  |  BCL11A  |  1.675  |  DISEASES
627  |  BDNF  |  2.095  |  DISEASES
831  |  CAST  |  1.641  |  DISEASES
875  |  CBS  |  2.268  |  DISEASES
1491  |  CTH  |  1.602  |  DISEASES
1629  |  DBT  |  3.763  |  DISEASES
1644  |  DDC  |  1.361  |  DISEASES
2108  |  ETFA  |  2.061  |  DISEASES
2271  |  FH  |  1.419  |  DISEASES
2328  |  FMO3  |  2.561  |  DISEASES
2878  |  GPX3  |  1.402  |  DISEASES
3033  |  HADH  |  3.221  |  DISEASES
3030  |  HADHA  |  1.018  |  DISEASES
3155  |  HMGCL  |  3.923  |  DISEASES
3329  |  HSPD1  |  2.588  |  DISEASES
3908  |  LAMA2  |  1.323  |  DISEASES
3939  |  LDHA  |  2.019  |  DISEASES
64087  |  MCCC2  |  3.12  |  DISEASES
219541  |  MED19  |  2.382  |  DISEASES
8972  |  MGAM  |  1.118  |  DISEASES
4803  |  NGF  |  1.015  |  DISEASES
4810  |  NHS  |  2.908  |  DISEASES
4942  |  OAT  |  1.217  |  DISEASES
5053  |  PAH  |  3.596  |  DISEASES
5096  |  PCCB  |  2.228  |  DISEASES
5277  |  PIGA  |  1.357  |  DISEASES
56980  |  PRDM10  |  1.112  |  DISEASES
387  |  RHOA  |  1.246  |  DISEASES
6281  |  S100A10  |  1.883  |  DISEASES
10165  |  SLC25A13  |  3.172  |  DISEASES
348932  |  SLC6A18  |  2.899  |  DISEASES
26812  |  SNORD37  |  4.407  |  DISEASES
55553  |  SOX6  |  2.125  |  DISEASES
54457  |  TAF7L  |  3.062  |  DISEASES
6898  |  TAT  |  1.614  |  DISEASES
23038  |  WDTC1  |  1.809  |  DISEASES
Locus(Waiting for update.)
Disease ID 27
Disease maple syrup urine disease
Integrated Phenotype
HPO | Name(Total Integrated Phenotypes:25)
HP:0001263  |  Global developmental delay
HP:0001507  |  Abnormal growth
HP:0000738  |  Sensory hallucination
HP:0001946  |  High levels of ketone bodies
HP:0000600  |  Abnormality of the pharynx
HP:0001251  |  Ataxia
HP:0001254  |  Lethargy
HP:0001943  |  Hypoglycemia
HP:0001315  |  Reduced tendon reflexes
HP:0004374  |  Hemiplegia/hemiparesis
HP:0001276  |  Hypertonia
HP:0001249  |  Mental retardation
HP:0008872  |  Feeding difficulties in infancy
HP:0001252  |  Hypotonia
HP:0001250  |  Seizures
HP:0002093  |  Respiratory insufficiency
HP:0003128  |  Lactic acidosis
HP:0001733  |  Pancreatic inflammation
HP:0001259  |  Coma
HP:0001608  |  Abnormality of the voice
HP:0008344  |  Elevated plasma branched chain amino acids
HP:0002181  |  Cerebral edema
HP:0001249  |  Intellectual disability
HP:0001252  |  Muscular hypotonia
HP:0002013  |  Emesis
Text Mined Phenotype
HPO | Name | Sentences' Count(Total Phenotypes:14)
HP:0001298  |  Encephalopathy  |  2
HP:0100022  |  Movement disorder  |  1
HP:0002901  |  Hypocalcemia  |  1
HP:0001250  |  Seizures  |  1
HP:0006846  |  Acute encephalopathy  |  1
HP:0002751  |  Kyphoscoliosis  |  1
HP:0012531  |  Pain  |  1
HP:0002500  |  Leukoaraiosis  |  1
HP:0001257  |  Spasticity  |  1
HP:0002181  |  Cerebral edema  |  1
HP:0100543  |  Cognitive deficits  |  1
HP:0001259  |  Coma  |  1
HP:0001733  |  Pancreatic inflammation  |  1
HP:0000969  |  Dropsy  |  1
Disease ID 27
Disease maple syrup urine disease
Manually Symptom
UMLS  | Name(Total Manually Symptoms:8)
C1963101  |  encephalopathy
C1306587  |  acute encephalopathy
C0848782  |  urological impairment
C0456909  |  blindness
C0392549  |  cerebral palsy
C0270921  |  axonal neuropathy
C0029089  |  ophthalmoplegia
C0020615  |  hypoglycemia
Text Mined Symptom
UMLS | Name | Sentences' Count(Total Symptoms:2)
C0085584  |  encephalopathy  |  2
C1306587  |  acute encephalopathy  |  1
Manually Genotype(Total Manually Genotypes:4)
Gene Mutation DOI Article Title
BCKDHAEx2_4dupdoi:10.1038/gim.2013.197Integration of targeted sequencing and NIPT into clinical practice in a Chinese family with maple syrup urine disease
BCKDHAc.392A>Gdoi:10.1038/gim.2013.197Integration of targeted sequencing and NIPT into clinical practice in a Chinese family with maple syrup urine disease
BCKDHBp.R183P45doi:10.1038/gim.2015.123Expanded genetic screening panel for the Ashkenazi Jewish population
BCKDHBp.G278Sdoi:10.1038/gim.2015.123Expanded genetic screening panel for the Ashkenazi Jewish population
Text Mining Genotype(Total Genotypes:0)
(Waiting for update.)
All Snps(Total Genotypes:73)
snpId pubmedId geneId geneSymbol diseaseId sourceId sentence score Year geneSymbol_dbSNP CHROMOSOME POS REF ALT
rs1202172096215121629DBTumls:C0024776UNIPROTMolecular basis of intermittent maple syrup urine disease: novel mutations in the E2 gene of the branched-chain alpha-keto acid dehydrogenase complex.0.5743402691998DBT1100206504TC
rs121964999NA1629DBTumls:C0024776CLINVARNA0.574340269NADBT1100214929AC
rs137852870NA593BCKDHAumls:C0024776CLINVARNA0.490801593NABCKDHA1941424582TA
rs137852871NA593BCKDHAumls:C0024776CLINVARNA0.490801593NABCKDHA1941422643GA,C
rs137852875NA593BCKDHAumls:C0024776CLINVARNA0.490801593NABCKDHA1941422704CG
rs149766077NA594BCKDHBumls:C0024776CLINVARNA0.49298306NABCKDHB680168944CG,T
rs182923857NA593BCKDHAumls:C0024776CLINVARNA0.490801593NABCKDHA1941423038CT
rs185492864NA1629DBTumls:C0024776CLINVARNA0.574340269NADBT1100214855GA
rs2893489511509994594BCKDHBumls:C0024776UNIPROTThese findings suggested that a limited number of mutations might underlie MSUD in the AJ population, potentially facilitating prenatal diagnosis and carrier detection of MSUD in this group.0.492983062001NANANANANA
rs37151812422326532594BCKDHBumls:C0024776BeFreeTwo novel mutations in the BCKDHB gene (R170H, Q346R) cause the classic form of maple syrup urine disease (MSUD).0.492983062012BCKDHB680168906GA,C
rs371518124NA594BCKDHBumls:C0024776CLINVARNA0.49298306NABCKDHB680168906GA,C
rs373713279NA593BCKDHAumls:C0024776CLINVARNA0.490801593NABCKDHA1941422278CA
rs375785084NA593BCKDHAumls:C0024776CLINVARNA0.490801593NABCKDHA1941422176CT
rs386834233NA594BCKDHBumls:C0024776CLINVARNA0.49298306NABCKDHB680201023GA
rs38683423317922217594BCKDHBumls:C0024776BeFreeAmong the known mutant alleles, p.Gly278Ser in the BCKDHB gene was relatively frequent and also associated with a mild MSUD variant.0.492983062007BCKDHB680201023GA
rs386834234NA594BCKDHBumls:C0024776CLINVARNA0.49298306NABCKDHB680343739GT
rs398123486NA593BCKDHAumls:C0024776CLINVARNA0.490801593NABCKDHA1941423039GA
rs398123489NA593BCKDHAumls:C0024776CLINVARNA0.490801593NABCKDHA1941410645C-
rs398123490NA593BCKDHAumls:C0024776CLINVARNA0.490801593NABCKDHA1941424504GA
rs398123491NA593BCKDHAumls:C0024776CLINVARNA0.490801593NABCKDHA1941424572CA,T
rs398123492NA593BCKDHAumls:C0024776CLINVARNA0.490801593NABCKDHA1941424580AC-
rs398123493NA593BCKDHAumls:C0024776CLINVARNA0.490801593NABCKDHA1941424584CA
rs398123494NA593BCKDHAumls:C0024776CLINVARNA0.490801593NABCKDHA;EXOSC51941397841T-
rs398123496NA593BCKDHAumls:C0024776CLINVARNA0.490801593NABCKDHA1941410817GA
rs398123497NA593BCKDHAumls:C0024776CLINVARNA0.490801593NABCKDHA1941410825CT
rs398123499NA593BCKDHAumls:C0024776CLINVARNA0.490801593NABCKDHA1941411004CT
rs398123503NA593BCKDHAumls:C0024776CLINVARNA0.490801593NABCKDHA1941419282CT
rs398123504NA593BCKDHAumls:C0024776CLINVARNA0.490801593NABCKDHA1941422257-T
rs398123508NA593BCKDHAumls:C0024776CLINVARNA0.490801593NABCKDHA1941422370GC
rs398123509NA593BCKDHAumls:C0024776CLINVARNA0.490801593NABCKDHA1941422680AC
rs398123510NA593BCKDHAumls:C0024776CLINVARNA0.490801593NABCKDHA1941422684GT-
rs398123512NA593BCKDHAumls:C0024776CLINVARNA0.490801593NABCKDHA1941422692T-
rs398123513NA593BCKDHAumls:C0024776CLINVARNA0.490801593NABCKDHA1941422739CT
rs398123515NA593BCKDHAumls:C0024776CLINVARNA0.490801593NABCKDHA1941422754GA
rs398123660NA1629DBTumls:C0024776CLINVARNA0.574340269NADBT1100196413GA
rs398123663NA1629DBTumls:C0024776CLINVARNA0.574340269NADBT1100196257AG
rs398123665NA1629DBTumls:C0024776CLINVARNA0.574340269NADBT1100235436CT
rs398123666NA1629DBTumls:C0024776CLINVARNA0.574340269NADBT1100230891ACTG-
rs398123667NA1629DBTumls:C0024776CLINVARNA0.574340269NADBT1100230821ATCATAA-
rs398123668NA1629DBTumls:C0024776CLINVARNA0.574340269NADBT1100230806T-
rs398123669NA1629DBTumls:C0024776CLINVARNA0.574340269NADBT1100249769CA
rs398123674NA1629DBTumls:C0024776CLINVARNA0.574340269NADBT1100214985TC
rs398123675NA1629DBTumls:C0024776CLINVARNA0.574340269NADBT1100214885GA
rs398123676NA1629DBTumls:C0024776CLINVARNA0.574340269NADBT1100214817CG
rs398124561NA594BCKDHBumls:C0024776CLINVARNA0.49298306NABCKDHB680273199CT
rs398124562NA594BCKDHBumls:C0024776CLINVARNA0.49298306NABCKDHB680343671GA
rs398124571NA594BCKDHBumls:C0024776CLINVARNA0.49298306NABCKDHB680129188GA
rs398124572NA594BCKDHBumls:C0024776CLINVARNA0.49298306NABCKDHB680106726AC-
rs398124573NA594BCKDHBumls:C0024776CLINVARNA0.49298306NABCKDHB680129228TG
rs398124574NA594BCKDHBumls:C0024776CLINVARNA0.49298306NABCKDHB680167677GA
rs398124576NA594BCKDHBumls:C0024776CLINVARNA0.49298306NABCKDHB680168876TG
rs398124577NA594BCKDHBumls:C0024776CLINVARNA0.49298306NABCKDHB680168885AT
rs398124581NA594BCKDHBumls:C0024776CLINVARNA0.49298306NABCKDHB680168905CA,G,T
rs398124582NA594BCKDHBumls:C0024776CLINVARNA0.49298306NABCKDHB680168923AT
rs398124586NA594BCKDHBumls:C0024776CLINVARNA0.49298306NABCKDHB680168989CA-
rs398124587NA594BCKDHBumls:C0024776CLINVARNA0.49298306NABCKDHB680168992AG-
rs398124589NA594BCKDHBumls:C0024776CLINVARNA0.49298306NABCKDHB680169031GA
rs398124592NA594BCKDHBumls:C0024776CLINVARNA0.49298306NABCKDHB680200939GT
rs398124593NA594BCKDHBumls:C0024776CLINVARNA0.49298306NABCKDHB680200943TC
rs398124594NA594BCKDHBumls:C0024776CLINVARNA0.49298306NABCKDHB680200990CG,T
rs398124596NA594BCKDHBumls:C0024776CLINVARNA0.49298306NABCKDHB680201033TG
rs398124598NA594BCKDHBumls:C0024776CLINVARNA0.49298306NABCKDHB680203114CT
rs398124600NA594BCKDHBumls:C0024776CLINVARNA0.49298306NABCKDHB680203163TG
rs398124601NA594BCKDHBumls:C0024776CLINVARNA0.49298306NABCKDHB680106786GGCGCGGGGCT-
rs398124602NA594BCKDHBumls:C0024776CLINVARNA0.49298306NABCKDHB680273134GA
rs398124603NA594BCKDHBumls:C0024776CLINVARNA0.49298306NABCKDHB680273153CT
rs727503895NA1629DBTumls:C0024776CLINVARNA0.574340269NADBT1100218751GTAACAAGGTAA-
rs74103423NA1629DBTumls:C0024776CLINVARNA0.574340269NADBT1100216085CA
rs786204699NA594BCKDHBumls:C0024776CLINVARNA0.49298306NABCKDHB680106796-GGCGCGGGGCT
rs794727262NA1629DBTumls:C0024776CLINVARNA0.574340269NADBT1100240810AC
rs794727635NA1629DBTumls:C0024776CLINVARNA0.574340269NADBT1100230732CA
rs794727847NA593BCKDHAumls:C0024776CLINVARNA0.490801593NABCKDHA1941422636AGGCCCCG-
rs79761867NA594BCKDHBumls:C0024776CLINVARNA0.49298306NABCKDHB680168945GC
GWASdb Annotation(Total Genotypes:0)
(Waiting for update.)
GWASdb Snp Trait(Total Genotypes:0)
(Waiting for update.)
Mapped by lexical matching(Total Items:7)
HP ID HP Name MP ID MP Name Annotation
HP:0008872Feeding difficulties in infancyMP:0011075abnormal macrophage activation involved in immune responseanomaly in the process in which a change in response and behavior of a macrophage results from exposure to a cytokine, chemokine, cellular ligand, or soluble factor, leading to the initiation or perpetuation of an immune response
HP:0003128Lactic acidosisMP:0003031acidosisa pathological state characterized by an increase in the hydrogen ion concentration in tissues and blood caused by an decrease in the concentration of alkaline compounds, or by a increase in the concentration of acidic compounds or carbon dioxide to the b
HP:0008344Elevated plasma branched chain amino acidsMP:0005311abnormal circulating amino acid levelany anomaly in the amount in the blood of a carboxylic acid containing one or more amino groups (-NH2) and a carboxyl (-COOH) group
HP:0001608Abnormality of the voiceMP:0013283failure of ventral body wall closurefailure of the lateral body wall folds (a combination of mesoderm and ectoderm arising on each side of the embryo) to progress ventrally and meet in the midline and/or fuse to close the ventral body wall; normally, this closure is aided by growth of the h
HP:0001263Global developmental delayMP:0002084abnormal developmental patterningabnormal systematic arrangement of the developing body along an axis
HP:0001252Muscular hypotoniaMP:0004144hypotoniadecreased muscle tension resulting in limpness of the muscles in the resting state, not to be confused with weakness
HP:0000600Abnormality of the pharynxMP:0010732abnormal node of Ranvier morphologyany structural anomaly of the short unmyelinated segments of an axon between myelinated segments, where voltage gated channels accumulate and regenerate an action potential as it is conducted along the axon
Mapped by homologous gene(Total Items:23)
HP ID HP Name MP ID MP Name Annotation
HP:0001252Muscular hypotoniaMP:3000003abnormal Ebner's gland morphologyany structural anomaly of the serous salivary glands which reside adjacent to the moats surrounding the circumvallate and foliate papillae just anterior to the posterior third of the tongue, anterior to the terminal sulcus; these exocrine glands secrete l
HP:0001250SeizuresMP:3000003abnormal Ebner's gland morphologyany structural anomaly of the serous salivary glands which reside adjacent to the moats surrounding the circumvallate and foliate papillae just anterior to the posterior third of the tongue, anterior to the terminal sulcus; these exocrine glands secrete l
HP:0001259ComaMP:0020216decreased circulating complement protein levelless than normal levels of the serum proteins that act sequentially to allow for the direct killing of microbes, the disposal of immune complexes, and the regulation of other immune processes
HP:0000600Abnormality of the pharynxMP:0020137decreased bone mineralizationdecrease in the rate at which minerals are deposited into bone
HP:0004374Hemiplegia/hemiparesisMP:3000003abnormal Ebner's gland morphologyany structural anomaly of the serous salivary glands which reside adjacent to the moats surrounding the circumvallate and foliate papillae just anterior to the posterior third of the tongue, anterior to the terminal sulcus; these exocrine glands secrete l
HP:0002093Respiratory insufficiencyMP:0020254decreased collagen leveldecreased level of the main structural protein of the various connective tissues in animals
HP:0003128Lactic acidosisMP:0020214susceptible to malignant hyperthermiaincreased susceptibility to hyperthermia triggered by exposure to certain drugs used for general anesthesia, specifically the volatile anesthetic agents and the neuromuscular blocking agent, succinylcholine
HP:0001263Global developmental delayMP:3000003abnormal Ebner's gland morphologyany structural anomaly of the serous salivary glands which reside adjacent to the moats surrounding the circumvallate and foliate papillae just anterior to the posterior third of the tongue, anterior to the terminal sulcus; these exocrine glands secrete l
HP:0001943HypoglycemiaMP:0020137decreased bone mineralizationdecrease in the rate at which minerals are deposited into bone
HP:0001276HypertoniaMP:0020316decreased vascular endothelial cell proliferationdecrease in the expansion rate of any vascular endothelial cell population by cell division
HP:0001249Intellectual disabilityMP:0020316decreased vascular endothelial cell proliferationdecrease in the expansion rate of any vascular endothelial cell population by cell division
HP:0001608Abnormality of the voiceMP:0020214susceptible to malignant hyperthermiaincreased susceptibility to hyperthermia triggered by exposure to certain drugs used for general anesthesia, specifically the volatile anesthetic agents and the neuromuscular blocking agent, succinylcholine
HP:0001254LethargyMP:0020137decreased bone mineralizationdecrease in the rate at which minerals are deposited into bone
HP:0001251AtaxiaMP:0020301short tonguedecreased length of the mobile mass of muscular tissue and surrounding epithelial tissue occupying the cavity of the mouth and forming part of the floor
HP:0008872Feeding difficulties in infancyMP:0020214susceptible to malignant hyperthermiaincreased susceptibility to hyperthermia triggered by exposure to certain drugs used for general anesthesia, specifically the volatile anesthetic agents and the neuromuscular blocking agent, succinylcholine
HP:0001507Growth abnormalityMP:0020254decreased collagen leveldecreased level of the main structural protein of the various connective tissues in animals
HP:0008344Elevated plasma branched chain amino acidsMP:0011086postnatal lethality, incomplete penetrancethe appearance of lower than Mendelian ratios of organisms of a given genotype due to death of some, but not all of the organisms anytime between the neonatal period and weaning age (Mus: P1 to approximately 3 weeks of age)
HP:0001733PancreatitisMP:0020134abnormal gallbladder sizean anomaly in the size of the gall bladder compared to average, the organ that serves as a storage reservoir for bile
HP:0000738HallucinationsMP:0020329decreased capillary densityreduction in the number of capillaries in a given cross-sectional area of a tissue
HP:0002013VomitingMP:0020316decreased vascular endothelial cell proliferationdecrease in the expansion rate of any vascular endothelial cell population by cell division
HP:0001946KetosisMP:0011110preweaning lethality, incomplete penetrancethe appearance of lower than Mendelian ratios of organisms of a given genotype due to death of some, but not all of the organisms between fertilization and weaning age (Mus: approximately 3-4 weeks of age)
HP:0002181Cerebral edemaMP:0013294prenatal lethality prior to heart atrial septationdeath prior to the completion of heart atrial septation (Mus: E14.5-15.5)
HP:0001315Reduced tendon reflexesMP:0020137decreased bone mineralizationdecrease in the rate at which minerals are deposited into bone
Disease ID 27
Disease maple syrup urine disease
Case(Waiting for update.)